Amaç: Difüzyon a¤›rl›kl› MR görüntüleme (DW-MRI) ve pozitron emisyon tomografi/bilgisayarl› tomografiyi (PET/BT) kullanarak gö-rünür difüzyon katsay›s›n›n (ADC) nicel de¤erleri, standardize edilmifl tutulum de¤eri (SUVmaks, SUVort), metabolik tümör volümü (MTV), metabolik tümör volüm göstergelerini (MTImaks ve MTIort) belirlemek ve ileri evre larenks kanserli homojen hasta grubunda bu biyobelirteç-lerin öngördürücü ve prognostik de¤erlerini incelemektir.
Laryngeal cancer is one of the most common type of head and neck cancers with an incidence of 5.1-10/100,000 worldwide. [1] In laryngeal cancer, the survival rates are 63-66% (5-year overall survival (OS) for glottic laryngeal cancer: 77% and 5-year OS for supraglottic laryngeal cancer: 51% for cancer). [2] [3] [4] However, the survival rates are suboptimal (≤50%) in patients with advanced-stage laryngeal cancer. [1, 2, [5] [6] [7] Currently, cross-sectional imaging is of utmost important for accurate staging and treatment planning. [8] Therefore, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) are frequently used for the imaging of patients with laryngeal cancer. In clinical practices, CT and/or MRI are generally recommended for the assessment of tumor extension and cervical lymph node involvement. [3, 5, 9] In addition, PET/CT is useful for the detection of lymph node metastasis, distant metastasis and second primary malignant neoplasms such as lung cancer. [10] [11] [12] [13] Remarkably, recent advancements in the field of imaging technologies demonstrate that Diffusion weighted-MRI (DW-MRI) and PET/CT may provide significant additional information which are called as "functional imaging-based biomarkers". These biomarkers are promising candidates for the understanding of intrinsic tumor biology and features, and may be helpful for the depiction of tumor microenvironment, prediction of treatment response and prognosis in patients with cancer. [14] [15] [16] [17] Briefly, DW-MRI, a form of functional MRI, evaluates the random motion of extracellular H2O molecules which is quantitatively expressed as apparent diffusion coefficient (ADC). In literature, an inverse relationship between ADC values and cell proliferation and density has been reported in different neoplasms such as breast cancers, neuroepithelial tumors and nasopharyngeal cancers. [16, 18, 19] Moreover, several studies have demonstrated lower ADC values (showing high tumor cellularity) in malignant tumors of head and neck despite of different cut-off values (ranging 0.84-1.455×10 -3 mm 2 /s). [20] [21] [22] [23] [24] [25] [26] In addition, PET/CT provides the measurement of different metabolic indexes such as standardized uptake values (SUV) and total lesion glycolysis (TLG), which is measured by metabolic tumor volume indexes (MTI), and volumetric parameters such as metabolic tumor volume (MTV) in several malignant neoplasms including cutaneous malignant melanoma, non-small cell lung cancer, bone and soft tissue sarcomas, brain tumors, breast cancers, renal cell carcinoma, T-cell leukemia, and head and neck cancers. [27] [28] [29] [30] [31] [32] [33] [34] However, the predictive and prognostic roles of abovementioned functional imaging-based biomarkers are unknown in patients with advanced-stage laryngeal cancer. Therefore, the purpose of the current study is to determine the quantitative values of ADC, SUV, SUVmax, SUVmean, MTV, MTImax, and MTImean using DW-MRI and PET/CT, and analyze the predictive and prognostic values of these biomarkers in a homogenous group of patients with advanced-stage laryngeal cancer.
Materials and Methods
This retrospective study was conducted in accordance with the Declaration of Helsinki and the study protocol was approved by the Institutional Ethics Committee. [35] 
Study population
The study population involved patients with advancedstage laryngeal cancer who had curative cancer treatment (surgery ± adjuvant therapy or radio ± chemotherapy) between 2011 and 2015. The exclusion criteria were as follows: (i) patients who had a recurrent tumor, (ii) patients who had a palliative treatment or patients who rejected treatment, and (iii) patients who did not have pretreatment MRI and/or PET/CT. Therefore, all patients were newly diagnosed advanced-stage laryngeal cancer, and had both DW-MRI and 18F-FDG PET/CT before treatment. All patients were followed up clinically and radiologically, if necessary every 3 months for the first 2 years, every 4-6 months for year 3, and then annually thereafter. Any sign of recurrence at primary tumor burden and/or neck was defined as locoregional recurrence. In addition, any metastatic lesion at a solid organ (e.g. lung, liver, bone, etc.) was accepted as distant metastasis.
MRI acquisition
All MRI examinations were performed on a 1. Neuroradiology and Head and Neck certified specialist who has a 12 years' experience in head and neck imaging), who was blinded to clinical staging and PET-CT data. Contrast enhanced-and STIR images were compared and fusion images were performed with ADC maps to define the whole tumor volume (Figs. 1a and 1b) . The regionsof-interests (ROI) included all tumors' volume excluding necrotic parts. Apparent diffusion coefficient mean values and standard deviations were recorded for each patient individually.
18F FDG PET/CT acquisition
All patients acquired whole body and spot F-18 FDG PET/CT (Philips, Medical Systems, Cleveland, OH, USA). All patients were asked to fast for at least 6 hours before scanning. A peripheral blood glucose level of less than 180 mg/dl was confirmed initially, and patients received an intravenous injection of 145 μCi/kg (maximum 200 μCi) of FDG afterwards. All images were obtained from base of skull to mid thigh level (Fig. 1b) . The SUVmax of primary tumor burdens and suspicious lymph node stations were detected automatically by the software after delineation of the ROI on attenuation-corrected PET/CT images. All F-18 FDG PET/CT scans were reevaluated by an author of the study (FA). Standardized uptake values (SUVmax and SUVmean), MTV and MTI (MTImax and MTImean) were calculated from primary tumor by automatic program.
Statistical analysis
All data were evaluated using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA). The descriptive results about study population and tumor characteristics were determined. Kolmogorov-Smirnov and Shapiro-Wilk tests demonstrated that study population was not normally distributed. Therefore, the predictive roles of ADC, SUV, SUVmax, SUVmean, MTV, MTImax, and MTImean were evaluated by Mann-Whitney U test. In addition, 2-year OS, locoregional control (LRC) and disease-free survival (DFS) were determined by Kaplan-Meier test. A "receiver operating characteristic" analysis was performed for a cut-off value of ADC value, SUV, SUVmax, SUVmean, MTV, MTImax, and MTImean; however, we were unable to determine a value with a high sensitivity and specificity. Therefore, the median values of ADC, SUV, SUVmax, SUVmean, MTV, MTImax, and MTImean were measured. Thereby, study population was separated into two groups as "low" and "high" according to the median values of each variable. Thereafter, survival analysis was performed using log rank test. A p-value of <0.05 was accepted statistically significant.
Results

Descriptive statistics
Thirty-eight patients (33 males, 86.8%; 5 females, 13.2%) with advanced-stage laryngeal cancer were retrospectively analyzed. Of these patients, 18 presented with supraglottic carcinoma (47.4%), 5 with glottic carcinoma (13.2%) and 15 with transglottic carcinoma (39.5%). With regard to tumor stage, 19 (50%) patients presented with T3 tumors, 19 (50%) with T4 tumors. The distribution of tumor grades were as follows: 3 patients (7.9 %) with well differentiated tumors, 20 patients (52.6%) with moderately differentiated tumors, 9 patients (23.7%) with poorly differentiated tumors. The mean value of age was 64.4 (range: 47 to 87) years; and only 5 patients were female. The 
Discussion
To the best of our knowledge, this is the first study in which various functional imaging-based biomarkers were evaluated in patients with advanced-stage laryngeal cancer using both DW-MRI and 18F-FDG PET/CT. Our literature review demonstrated that few clinical studies reported the role of both imaging techniques in head and neck cancers [15, [36] [37] [38] [39] [40] [41] (Table 3) . However, the major drawback of these studies was the clinical heterogeneity of study groups in which patients with different primary tumor burdens (e.g. oropharynx, hypopharynx, nasopharynx, larynx and oral cavity) and stages were included. As a matter of fact, the measured ADC, SUV, MTV and TLG and clinical outcomes might vary significantly between abovementioned study groups. In addition, as Zhang et al. emphasized, small head and neck neoplasms are generally difficult to detect using DW-MRI; hence, the ADC values are generally unreliable. [16] Therefore, patients with early-stage laryngeal cancer were not enrolled into this study, and a homogenous group of patients with advanced-stage laryngeal cancer was particularly selected in order to determine reliable relationships between all functional imaging-based biomarkers and tumor characteristics or clinical outcomes; thereby, study group related misconceptions were minimized.
ENT Updates
Eskiizmir G et al. In laryngeal cancer, the association between pretreatment functional imaging-based biomarkers and tumor characteristics such as grade, neoplastic invasion or stage are inconclusive. In general, poorly differentiated tumors have more aggressive behavior and tendency to metastasize and recur. In addition, tumor cellularity is frequently high in poorly differentiated tumors. A recent meta-analysis demonstrated a moderate inverse correlation between ADC value and tumor cellularity in head and neck cancers, even though the number of included cases was less than 50 patients. [42] However, the authors emphasized that the association between ADC value and tumor cellularity var-
Eskiizmir G et al. ied significantly in different types of cancers with an inconsistent data between clinical studies. They also speculated that the variability in results might be related with tumor features (cellular proliferation, nucleic areas, etc.) and microenvironment (stroma-parenchyma ratio, microvessel density, necrotic areas, etc.). In fact, Driessen et al. were unable to detect an association between ADC value and tumor grade. [43] Similarly, our results demonstrated that none of the functional based-imaging biomarkers was associated with tumor differentiation ( Table  2) . In clinical practices, the detection of neoplastic invasion of thyroid cartilage is of utmost important for treatment selection and strategy, and prognosis. Currently, CT and/or MRI are frequently used despite of inadequate sensitivity, specificity, and positive and negative predictive values. [44, 45] Therefore, novel techniques are required for the improvement of these imaging modalities. Hence, Taha et al. reported that DW-MRI had high sensitivity and specificity for the prediction of TCI in patients with laryngeal cancer; however, the authors did not give any information about ADC values. [46] In addition, Kendi et al. evaluated several PET/CT-based imaging biomarkers including SUVmax, SUVmean, SUVpeak, MTV, TLG, standardized added metabolic activity and normalized standardized added metabolic activity in patients with larynx cancer, and reported that none of the forementioned parameters was either sensitive or specific enough for the prediction of TCI. [47] In this study, we were also unable to detect an association between pretreatment functional imaging-based biomarkers and TCI ( Table 2) .
In fact, patients with advanced-stage head and neck cancers have a tendency to have high PET/CT-based
Eskiizmir G et al. Table 3 . Systemic review of clinical studies in which the predictive and/or prognostic roles of both DW-MRI and PET/CT were assessed in patients with head and neck cancers.
imaging biomarkers. [37, 48] 3, p=0.20) . It is noteworthy that lower pretreatment ADC values were reported in metastatic cervical lymph nodes. [49] [50] [51] [52] On the other hand, Sumi et al. detected lower pretreatment ADC values in benign lymph nodes when compared with metastatic lymph nodes. [53] Presumably, the reason for this discrepancy might be related with tumor heterogeneity and presence/absence of necrotic portions in lymph nodes. [54] Moreover, Kwee et al. emphasized the limitations in intraand interobserver reproducibility of ADC measurements of lymph nodes. [55] In laryngeal cancers, the prognostic role of pretreatment functional based-imaging biomarkers remains controversial. In this study, no correlation between pretreatment ADC values and oncological outcomes including 2-year OS, LRC and DFS was determined (Fig. 2) . It is noteworthy that our literature review was unable to determine a clinical study which was particularly focused on the prognostic role of pretreatment ADC value in patients with laryngeal cancer. However, Hatakenaka et al. examined the prognostic role of pretreatment ADC values in patients treated with radiotherapy for head and neck cancers and determined high risk of local failure in patients with high pretreatment ADC value. [56] Similarly, Preda et al. emphasized that high pretreatment ADCmin value (cut-off value: 0.58×10 -3 mm 2 /s) was a poor prognostic factor for patients with head and neck cancer. [40] In contrast, Nakajo et al. reported a significant decrease in 2-year DFS in patients with low pretreatment ADC value (cut-off value: 0.88×10 mm 2 /s). [37] Nevertheless, both Preda et al. (cut-off value: 5.75) and Nakajo et al. (cutoff value: 12.1) demonstrated an inverse correlation between pretreatment SUV of primary tumor and survival in patients with head and neck cancers. However, Park et al. were unable to determine a statistically significant correlation between pretreatment SUVmax (cut-off value: 10) and oncological outcomes including 3-year LRC and OS in patients with laryngeal and hypopharyngeal cancer. [57] On the other hand, Kitajima et al. particularly evaluated the prognostic value of pretreatment SUV in patients with laryngeal cancer and reported that pretreatment SUV of primary tumor (cutoff value: 2.85) was a prognostic imaging biomarker for patients who were treated by radio±chemotherapy. [58] Interestingly, they did not find a correlation between pretreatment SUV of primary tumor (cut-off value: 8.6) and survival in patients who were treated by surgery with/without adjuvant treatment. In contrast, Joo et al. reported that patients who were treated by supracricoid laryngectomy had unfavorable outcome and poor prognosis when the pretreatment SUVmax of primary tumor was higher than 7.0. [59] In our study, we were unable to determine a correlation between pretreatment SUV (cut-off value: 11.3), SUVmax (cut-off value: 12.4), and SUVmean (cut-off value: 4.8) of primary tumor and oncological outcomes (Fig. 3) . It is known that patient related-(e.g. plasma glucose level, body mass index, etc.), tumor related-(e.g. tumor size, shape and microenvironment) and technique related-factors (e.g. post-injection PET scan time, acquisition protocol, imaging procedure, software, etc.) may affect the measured SUV values. Therefore, a variety of novel quantification techniques such as MTV and TLG were presented recently. A systematic review and meta-analysis demonstrated that MTV and TLG were prognostic imaging biomarkers for patients with head and neck cancers, and high MTV and TLG values caused more than 3-fold increase in mortality risk. [60] However, the authors also noted that their study had several limitations including different cut-off values for MTV and TLG, protocol related measurement changes, and clinical heterogeneity (e.g. primary tumor burden, tumor differentiation and stage) in head and neck cancers. Nonetheless, Yabuki et al. determined an inverse correlation between pretreatment MTV values (cut-off value: 4.9 ml) and survival in patients who were treated by radio+chemotherapy for laryngeal cancer. [61] Furthermore, same group also reported that patients with high pretreatment MTV values (cut-off value: 4.9 ml) had better survival outcomes when surgery-based treatment strategy was performed. [62] Hence, they suggested that MTV might be used for treatment selection in laryngeal cancer. As abovementioned, our study population was composed of patients with advanced-stage laryngeal cancer; therefore, the median value for MTV (cut-off value: 25.8 ml) was remarkably higher than forementioned studies. However, our results did not show a survival difference between patients with high and low MTV values (Fig. 3) .
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Conclusions
This is the first study that particularly focused on evaluating the predictive and prognostic roles of pretreatment functional imaging-based biomarkers in patients with advancedstage laryngeal cancer. Our results obviously demonstrated that pretreatment SUV and MTImean values were predictive factors for staging, N-stage and PNI. Indeed, functional imaging-based biomarkers are promising, novel, non-invasive techniques that may provide additional information about tumor characteristics, treatment selection and prognosis in the near future. However, tumor-and protocol related differences are the major drawbacks. Therefore, well-stratified, multicenter, prospective clinical studies with tumor-specific standardized cut-off values and protocols are required.
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